CHRDL2

Across TCGA pan-cancer cohorts, CHRDL2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CHRDL2 data layer compared with 18 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where higher CHRDL2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CHRDL2 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

PRAD, SCLC, and SARC are the cancer types where CHRDL2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SCLC	DFS	Median	III,IV	0.137	0.546	.042	6	view →
SARC	DFS	Median	All	0.198	0.614	.010	3	view →
SKCM	DFS	Median	III,IV	1.000	0.467	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CHRDL2–PRAD (DFS)

Open the PRAD breakdown →